Literature DB >> 10618270

Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein.

P Colque-Navarro1, M Palma, B Söderquist, J I Flock, R Möllby.   

Abstract

We analyzed the serum antibody responses against two Staphylococcus aureus fibrinogen binding proteins, the cell-bound clumping factor (Clf) and an extracellular fibrinogen binding protein (Efb). The material consisted of 105 consecutive serum samples from 41 patients suffering from S. aureus septicemia and 72 serum samples from healthy individuals. An enzyme-linked immunosorbent assay (ELISA) was developed. Healthy individuals showed variable levels of antibodies against the studied antigens, and cutoff levels (upper 95th percentile) against these antigens were determined. No correlation was seen between serum antibody levels against Clf and Efb. In acute-phase samples 27% of patients showed positive antibody levels against Clf and 10% showed positive levels against Efb, while in convalescent-phase samples 63% (26 of 41) showed a positive serology against Clf and 49% (20 of 41) showed a positive serology against Efb. Antibody levels against Efb were significantly lower in the acute-phase sera than in sera from healthy individuals (P = 0. 002). An antibody response against Clf was most frequent in patients suffering from osteitis plus septic arthritis and from endocarditis (80% positive). The antibody response against Efb appeared to develop later in the course of disease. A possible biological effect of measured antibodies was demonstrated with the help of an inhibition ELISA, in which both high-titer and low-titer sera inhibited the binding of bacteria to fibrinogen. In conclusion, we have demonstrated in vivo production of S. aureus fibrinogen binding proteins during deep S. aureus infections and a possible diagnostic and prophylactic role of the corresponding serum antibodies in such infections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618270      PMCID: PMC95815          DOI: 10.1128/CDLI.7.1.14-20.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  Evidence for three different fibrinogen-binding proteins with unique properties from Staphylococcus aureus strain Newman.

Authors:  M K Bodén; J I Flock
Journal:  Microb Pathog       Date:  1992-04       Impact factor: 3.738

2.  Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model.

Authors:  E Reizenstein; H O Hallander; W C Blackwelder; I Kühn; M Ljungman; R Möllby
Journal:  J Immunol Methods       Date:  1995-06-28       Impact factor: 2.303

Review 3.  Surface-associated proteins of Staphylococcus aureus: their possible roles in virulence.

Authors:  T J Foster; D McDevitt
Journal:  FEMS Microbiol Lett       Date:  1994-05-15       Impact factor: 2.742

4.  Vaccination with Staphylococcus aureus fibrinogen binding proteins (FgBPs) reduces colonisation of S. aureus in a mouse mastitis model.

Authors:  W Mamo; M Bodén; J I Flock
Journal:  FEMS Immunol Med Microbiol       Date:  1994-11

5.  Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus.

Authors:  D McDevitt; P Francois; P Vaudaux; T J Foster
Journal:  Mol Microbiol       Date:  1995-06       Impact factor: 3.501

6.  Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis.

Authors:  P Moreillon; J M Entenza; P Francioli; D McDevitt; T J Foster; P François; P Vaudaux
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  Serological response to toxic shock syndrome toxin in Staphylococcus aureus infected patients and healthy controls.

Authors:  B Christensson; S A Hedström
Journal:  Acta Pathol Microbiol Immunol Scand B       Date:  1985-04

8.  Lipase versus teichoic acid and alpha-toxin as antigen in an enzyme immunoassay for serological diagnosis of Staphylococcus aureus infections.

Authors:  S Tyski; P Colque-Navarro; W Hryniewicz; M Granström; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-05       Impact factor: 3.267

9.  Serological assays against Staphylococcus aureus peptidoglycan, crude staphylococcal antigen and staphylolysin in the diagnosis of serious S. aureus infections.

Authors:  B Christensson; F Espersen; S A Hedström; G Kronvall
Journal:  Scand J Infect Dis       Date:  1985

10.  Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8.

Authors:  B Christensson; A Boutonnier; U Ryding; J M Fournier
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

View more
  21 in total

1.  Constitutive production of catalytic antibodies to a Staphylococcus aureus virulence factor and effect of infection.

Authors:  Eric L Brown; Yasuhiro Nishiyama; Jesse W Dunkle; Shreya Aggarwal; Stephanie Planque; Kenji Watanabe; Keri Csencsits-Smith; M Gabriela Bowden; Sheldon L Kaplan; Sudhir Paul
Journal:  J Biol Chem       Date:  2012-02-02       Impact factor: 5.157

2.  Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population.

Authors:  Patricia Colque-Navarro; Gunnar Jacobsson; Rune Andersson; Jan-Ingmar Flock; Roland Möllby
Journal:  Clin Vaccine Immunol       Date:  2010-05-05

3.  Antibody responses in patients with invasive Staphylococcus aureus infections.

Authors:  G Jacobsson; P Colque-Navarro; E Gustafsson; R Andersson; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-10       Impact factor: 3.267

4.  Genetic variation among hospital isolates of methicillin-sensitive Staphylococcus aureus: evidence for horizontal transfer of virulence genes.

Authors:  P C Moore; J A Lindsay
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

5.  Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Authors:  Paul J Domanski; Pratiksha R Patel; Arnold S Bayer; Li Zhang; Andrea E Hall; Peter J Syribeys; Elena L Gorovits; Dawn Bryant; John H Vernachio; Jeff T Hutchins; Joseph M Patti
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Periodic vicissitudes of different concentrations of a developed prototype killed S. aureus mastitis vaccine on immune modulators, mediators and immunoglobulins in cows.

Authors:  Idris Umar Hambali; Faez Firdaus Jesse Bin Abdullah; K R Bhutto; M L Mohd Azmi; A H Wahid; Z Zakaria; M N Odhah; M Arsalan; N A Muhammad; M N Jefri
Journal:  Trop Anim Health Prod       Date:  2018-11-17       Impact factor: 1.559

7.  Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.

Authors:  Agnieszka Dryla; Sonja Prustomersky; Dieter Gelbmann; Markus Hanner; Edith Bettinger; Béla Kocsis; Tamás Kustos; Tamás Henics; Andreas Meinke; Eszter Nagy
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

8.  An Enterococcus faecium secreted antigen, SagA, exhibits broad-spectrum binding to extracellular matrix proteins and appears essential for E. faecium growth.

Authors:  Fang Teng; Magdalena Kawalec; George M Weinstock; Waleria Hryniewicz; Barbara E Murray
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Molecular characterization of endocarditis-associated Staphylococcus aureus.

Authors:  Cara Nethercott; Amanda N Mabbett; Makrina Totsika; Paul Peters; Juan C Ortiz; Graeme R Nimmo; Geoffrey W Coombs; Mark J Walker; Mark A Schembri
Journal:  J Clin Microbiol       Date:  2013-04-24       Impact factor: 5.948

10.  Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro.

Authors:  Thomas Weichhart; Markus Horky; Johannes Söllner; Susanne Gangl; Tamàs Henics; Eszter Nagy; Andreas Meinke; Alexander von Gabain; Claire M Fraser; Steve R Gill; Martin Hafner; Uwe von Ahsen
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.